The heart fail­ure mar­ket gets a lit­tle more crowd­ed, as Eli Lil­ly and Boehringer In­gel­heim score a win for Jar­diance

Watch out, Farx­i­ga: There’s an­oth­er SGLT2 in­hibitor ap­proved to treat heart fail­ure pa­tients with re­duced ejec­tion frac­tion (HFrEF).

On Wednes­day, Eli Lil­ly and Boehringer In­gel­heim se­cured a win for Jar­diance in HFrEF, a con­di­tion where the mus­cle of the left ven­tri­cle doesn’t pump nor­mal­ly. The in­di­ca­tion ac­counts for more than half of heart fail­ure pa­tients, and the risk of death in­creas­es with each hos­pi­tal­iza­tion, ac­cord­ing to the part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER